HDL-3 is a Superior Predictor of Carotid Artery Disease in a Case-Control Cohort of 1725 Participants

Daniel Seung Kim, BS; Amber A. Burt, MS; Elisabeth A. Rosenthal, PhD; Jane E. Ranchalis, BS; Jason F. Eintracht, MD; Thomas S. Hatsukami, MD; Clement E. Furlong, PhD; Santica Marcovina, PhD, DSc; John J. Albers, PhD; Gail P. Jarvik, MD, PhD

Background—Recent data suggest that high-density lipoprotein cholesterol (HDL-C) levels are likely not in the causative pathway of atheroprotection, shifting focus from HDL-C to its subfractions and associated proteins. This study’s goal was to determine which HDL phenotype was the better predictor of carotid artery disease (CAAD).

Methods and Results—HDL-2 and HDL-3 were measured in 1725 participants of European ancestry in a prevalent case-control cohort study of CAAD. Stratified analyses were conducted for men (n=1201) and women (n=524). Stepwise linear regression was used to determine whether HDL-C, HDL-2, HDL-3, or apolipoprotein A1 was the best predictor of CAAD, while adjusting for the confounders of censored age, diabetes, and current smoking status. In both men and women, HDL-3 was negatively associated with CAAD (P<0.0011 and 0.033 for men and women, respectively); once HDL-3 was included in the model, no other HDL phenotype was significantly associated with CAAD. Addition of paraoxonase 1 activity to the aforementioned regression model showed a significant and independent (of HDL-3) association with CAAD in men (P<0.001) but not in the smaller female subgroup.

Conclusions—This study is the first to contrast the associations of HDL-2 and HDL-3 with CAAD. We found that HDL-3 levels were more predictive of CAAD status than HDL-2, HDL-C, or apolipoprotein A1. In addition, for men, paraoxonase 1 activity improved the overall model prediction for CAAD independently and additively with HDL-3 levels. Further investigation into the molecular mechanisms through which HDL-3 is associated with protection from CAAD is warranted. (J Am Heart Assoc. 2014;3:e000902 doi: 10.1161/JAHA.114.000902)

Key Words: atherosclerosis • carotid arteries • high-density lipoprotein • lipids • lipoproteins

Cardiovascular disease (CVD) is one of the leading causes of death in the developed world.1 Stroke, considered independently of other CVD, is the fourth leading cause of death and the leading cause of disability in the United States1 and the second leading cause of death globally.2 Atherosclerosis in the carotid arteries can be assessed noninvasively and quantitatively through use of ultrasonography.3 Significant atherosclerosis in the carotid arteries is diagnosed as carotid artery disease (CAAD).3–5 CAAD severity is directly related to risk of stroke.3–5 Notably, severe CAAD is found in 4.2% of men and 2% of women, respectively, in the 60- to 69-year-old age group.6 In addition, CAAD is predictive of death from CVD: patients with symptomatic CAAD have a 1-year event rate of 14.5% for cardiovascular death, myocardial infarction, or stroke.7 Despite strong observational evidence in support of high-density lipoprotein cholesterol (HDL-C) levels being cardio-protective,8 HDL-C has recently failed in 2 attempts to establish causality. In the first of these studies, HDL-C was studied in the setting of a randomized clinical trial of 3414 patients with established coronary heart disease (CHD), with the primary end point of any adverse cardiovascular event.9 Patients were randomized to niacin or placebo. At the 2-year follow-up, patients randomized to niacin had significantly higher levels of HDL-C. Despite the higher levels of HDL-C, the rate of adverse cardiovascular events was not significantly different than that of the placebo group (P=0.79). Separately, a mendelian randomization study studied the effects of a single nucleotide polymorphism in the endothelial lipase gene (LIPG<sub>Asn396Ser</sub>), known to increase HDL-C.10 As expected, carriers of the LIPG<sub>Asn396Ser</sub> single nucleotide polymorphism...
HDL-3 Predicts Carotid Artery Disease

Kim et al

had significantly higher levels of HDL-C; however, the \textit{LIPG} Asn396Ser single nucleotide polymorphism was not associated with risk of myocardial infarction ($P=0.85$). Together, the failure of these 2 studies to establish a causal link between HDL-C level and cardiovascular disease has raised new doubts regarding the cardioprotective nature of HDL.

More recent evidence from the Multi-Ethnic Study of Atherosclerosis (MESA) has revealed a possible explanation for the negative results of HDL-C and cardiovascular events.\textsuperscript{11} In this study, Mackey et al. evaluated the association of HDL-C and HDL particle concentration measured by nuclear magnetic resonance spectroscopy (HDL-P) with incident CHD (n=227 events). As expected, HDL-C and HDL-P were highly correlated (Spearman’s correlation coefficient of 0.69, $P<0.001$); however, in multivariate regression models, HDL-P was the superior predictor of incident CHD in comparison to HDL-C. This finding indicated that although HDL-C captured a large portion of HDL-P variation, HDL-C measurements alone did not reflect the individual elements of HDL captured by HDL-P that were primarily responsible for cardioprotection.

Aspects of HDL that are not captured by HDL-C include its immensely complex proteome, with recent estimates of 64 associated proteins.\textsuperscript{12} Broadly, HDL is composed of 2 subspecies, HDL-2 and HDL-3, that can be separated by ultracentrifugation and electrophoresis.\textsuperscript{13} Both HDL-2 and HDL-3 have distinct biochemical, physiologic, and metabolic functions.\textsuperscript{13} Investigations contrasting the cardioprotection of HDL-2 or HDL-3 have yielded conflicting results, with aspects of both subspecies being associated with decreased risk of CVD.\textsuperscript{13}

Given the recent evidence suggesting that HDL-C level does not have a direct causal role in cardioprotection, we hypothesized that specific aspects of HDL not completely correlated with HDL-C level were superior predictors of CAAD, as defined by >50% stenosis in either carotid artery. Specifically, we sought to determine whether the level of one of the 2 subspecies of HDL (HDL-2 versus HDL-3) was a superior predictor of CAAD status in a prevalent case-control cohort from the Carotid Lesion Epidemiology and Risk (CLEAR) study, a Seattle, Washington-based repository composed primarily of veterans that was collected to identify risk factors for CAAD, CAAD progression, and other atherosclerotic disease end points. In addition, we attempted to elucidate whether functional aspects of HDL, such as its associated proteins apolipoprotein A1 (apoA1) and paraoxonase 1 (PON1), independently predicted further CAAD status.

Methods

Ethics Statement

Institutional review boards at the University of Washington, Virginia Mason Medical Center, and Veterans Affairs Puget Sound approved the CLEAR study. Written, informed consent was obtained from each participant of the study.

Sample

The CLEAR study is a Seattle-based prevalent CAAD case-control study composed primarily of veterans, with controls matched by age at diagnosis (for CAAD cases) and current unaffected age (for controls). Exclusion criteria included familial hypercholesterolemia, total fasting cholesterol >400 mg/dL, hypocoagulable state and/or the use of anticoagulant medication, previous organ transplant, or the inability to provide consent. All participants underwent ultrasound assessment of their carotid arteries for the presence or absence of atherosclerotic plaque except for a small number of participants with CAAD that had a prior carotid endarterectomy for symptomatic obstruction. CAAD case status was defined as >50% stenosis in either carotid artery as determined by ultrasound, whereas controls were also imaged and had <15% stenosis in both carotid arteries and absence of peripheral artery disease or CHD. The cohort consisted of 688 CAAD cases and 1037 controls. The few participants with moderate carotid stenosis (15% to 49% obstruction in at least one carotid artery) were excluded from analysis. Censored age was the age at CAAD diagnosis for cases and age at enrollment and blood draw for controls. Current smoking status was obtained by self-report. Insulin use was determined by self-report matched to hospital pharmacy records.

The study population for this analysis consisted of 1725 European-ancestry participants from the previously described CLEAR study.\textsuperscript{14–20} To avoid population stratification, smaller numbers of participants with non-European ancestry were excluded from all analyses presented in this paper. European genetic ancestry was confirmed by principal components analysis using STRUCTURE\textsuperscript{21} and single nucleotide polymorphisms from the Illumina CVD chip\textsuperscript{22,23} or 550k BeadChip data. Descriptive statistics of the cohort are presented in Table 1.

Lipid Measurements

Standard methods were used to determine total cholesterol, triglycerides, and HDL in fasting whole plasma using an Abbott Spectrum analyzer. HDL fractions 2 and 3 were determined by precipitating HDL-2 from isolated total HDL, measuring HDL-3 in the supernatant, and subtracting this from total HDL to obtain HDL-2. ApoA1 was measured as previously described.\textsuperscript{24} PON1 activity was measured by the rate of enzymatic degradation of phenylacetate (AREase) by a continuous spectrophotometric assay with lithium heparin plasma, as AREase is least affected by the functional $PON1_{Q192R}$ polymorphism and also is more closely related.
to PON1 protein levels.\textsuperscript{25,26} PON1 AREase activity was measured in triplicate and averaged. All lipid and associated protein measurements had approximate standard distributions. All data were generated blinded to CAAD status.

### Statistical Analyses

Analyses were done in R (http://www.r-project.org/) using the available standard regression tools. All participants had complete phenotype and covariate data for regression analyses. Because there is a known sex-dependent difference in HDL levels, we chose to perform sex-stratified analyses.

Sex-specific analyses comparing risk factors between CAAD cases and controls used either the Wilcoxon rank sum test (for continuous variables) or Pearson’s chi-square test (for categorical variables) to determine significance. Correlation of covariates was summarized using Pearson’s pairwise correlation coefficient.

Given the high correlation between the measurements, we performed stepwise logistic regression on the phenotype of CAAD, with HDL-C, HDL-2, HDL-3, and apoA1 entering the model. Model comparison was done using Akaike’s information criterion, beginning with a base model composed of the known confounders of CAAD status: censored age, diabetes status, and current smoking status. The measurement that best improved model prediction of CAAD via Akaike’s information criterion was retained in the final model. A secondary analysis considered the addition of PON1 AREase activity to HDL-3 levels and performed stepwise logistic regression, also considering censored age, current smoking, and diabetes status, to determine whether PON1 AREase activity predicted additional CAAD variance independent of the other lipid measurements.

Statin drug use can also affect HDL levels; however, because CAAD is treated with statins, statin use was confounded for CAAD status and could not be included in a model predicting CAAD. We noted the increase in HDL levels in the CLEAR data was not statistically significant in 57 male CLEAR participants with repeat lipid measurements before and after statin initiation. Although HDL levels do increase with statin use, the increase was not statistically significant (HDL-C, \(P=0.14\); HDL-2, \(P=0.57\); HDL-3, \(P=0.27\); Table 2).

### Results

Demographic, clinical, and lipid variables of the studied European-ancestry subset of the CLEAR cohort are presented

| Table 1. Baseline Characteristics of the Studied European-Ancestry Subset of CLEAR, Stratified by Sex |
|------------------------------------------------|
| | Women (N=524) | Men (N=1201) | Combined (N=1725) |
|-----------------|-----------------|-----------------|-----------------|
| apoA1, IU       | 166±28          | 138±26          | 146±29          |
| HDL-C, mg/dL    | 63±18           | 47±15           | 52±18           |
| HDL-2, mg/dL    | 14.7±7.8        | 8.5±5.3         | 10.4±6.8        |
| HDL-3, mg/dL    | 49±11           | 39±11           | 42±12           |
| PON1 AREase activity, IU | 167±58 | 132±49 | 143±55 |
| Current smoker  | 6% (32)         | 17% (199)       | 13% (231)       |
| Statin use      | 24% (124)       | 40% (482)       | 35% (606)       |
| Diabetic        | 9% (46)         | 22% (268)       | 18% (314)       |
| Censored age, years* | 63.6±9.8 | 68.0±9.4 | 66.6±9.7 |
| CAAD status     | 19% (102)       | 49% (586)       | 40% (688)       |

Mean±1 SD. Numbers after percents are counts. apoA1 indicates apolipoprotein A1; AREase, PON1 arylester hydrolysis rate; CAAD, carotid artery disease; CLEAR, Carotid Lesion Epidemiology and Risk; HDL-C, high-density lipoprotein cholesterol.

*Censored age defined as the age at CAAD diagnosis (for CAAD cases) or the age at enrollment of controls.

| Table 2. Effect of Statin Use on HDL-C, HDL-2, and HDL-3 Concentration in a Male-Only Subset of CLEAR With Repeat Lipid Measures Before and After Statin Use (n=57) |
|-----------------------------------|
| | Before Statin | After Statin | \(P\) Value* |
|-----------------|-----------------|-----------------|
| HDL-C           | 42.63±13.03     | 46.44±13.78     | 0.14          |
| HDL-2           | 6.91±3.99       | 7.28±4.23       | 0.57          |
| HDL-3           | 35.72±9.47      | 37.38±10.51     | 0.27          |

Mean±1 SD. HDL indicates high-density lipoprotein cholesterol.

*Tests used: 2-sample, 2-sided \(t\) test without the assumption of equal variance.
in Table 1. The cohort was composed of 1201 men and 524 women, of which 586 men (49%) and 102 women (19%) had CAAD. Women had lower rates of smoking (6% versus 19%), statin use (24% versus 40%), and diabetes (9% versus 22%). In addition, women had higher levels of all HDL phenotypes (HDL-C, HDL-2, HDL-3, apoA1 and PON1). Due to these sex-dependent differences in lipid and clinical covariates, stratified analyses were conducted to determine which HDL measure was the better predictor of CAAD.

There were significant (P<0.05) differences for all clinical and lipid covariates between CAAD participants and controls for both men (Table 3) and women (Table 4). Those with CAAD had significantly lower levels of apoA1, HDL-C, HDL-2, HDL-3, and PON1 AREase activity compared with controls for both men and women and also had significantly higher rates of current smoking and diabetes. In addition, censored age was higher for both male and female participants with CAAD when compared with controls.

The pairwise correlation between each of the studied clinical and lipid covariates was considerable (Figure 1). ApoA1, HDL-C, HDL-2, and HDL-3 were all strongly and positively correlated with each other (pairwise correlation coefficients, r≥0.75). PON1 AREase activity was also positively correlated with the other lipid measurements, albeit not as strongly (r≥0.26). Current smoking status and diabetes were each negatively correlated with each of the aforementioned lipid measurements, although they were not highly correlated with each other (r=0.04).

In men, HDL-3 was the lipid measurement that explained the greatest amount of CAAD variation (1.6%) and was

Table 3. Association of Baseline Lipid and Clinical Characteristics With CAAD Status in Men (N=1201)

|                      | Controls (N=615) | CAAD Cases (N=586) | P Value*†‡ |
|----------------------|------------------|--------------------|------------|
| apoA1, IU            | 142±26           | 133±24             | <0.001*    |
| HDL-C, mg/dL         | 50±16            | 44±13              | <0.001*    |
| HDL-2, mg/dL         | 9.2±5.7          | 7.9±4.8            | <0.001*    |
| HDL-3, mg/dL         | 40.6±11.2        | 36.4±9.4           | <0.001*    |
| PON1 AREase activity, IU | 145±49          | 119±46             | <0.001*    |
| Current smoker       | 9% (54)          | 25% (145)          | <0.001†    |
| Statin use           | 18% (112)        | 63% (367)          | <0.001†    |
| Diabetic             | 13% (82)         | 32% (186)          | <0.001†    |
| Censored age, years  | 64.9±9.0         | 71.2±8.7           | <0.001*    |

Mean±1 SD. Numbers after percents are frequencies. apoA1 indicates apolipoprotein A1; AREase, PON1 arylester hydrolysis rate; CAAD, carotid artery disease; HDL-C, high-density lipoprotein cholesterol. Tests used: *Wilcoxon rank sum test; †Pearson chi-square test. ‡Censored age defined as the age at CAAD diagnosis (for CAAD cases) or the age at enrollment of controls.

Table 4. Association of Baseline Lipid and Clinical Characteristics With CAAD Status in Women (N=524)

|                      | Controls (N=422) | CAAD Cases (N=102) | P Value*†‡ |
|----------------------|------------------|--------------------|------------|
| apoA1, IU            | 167±27           | 160±30             | 0.021*     |
| HDL-C, mg/dL         | 65±17            | 59±19              | <0.001*    |
| HDL-2, mg/dL         | 15.1±7.7         | 13.1±7.7           | 0.003*     |
| HDL-3, mg/dL         | 50±11            | 45±12              | <0.001*    |
| PON1 AREase activity, IU | 171±58          | 150±57             | <0.001*    |
| Current smoker       | 5% (20)          | 12% (12)           | 0.008†     |
| Statin use           | 14% (57)         | 66% (67)           | <0.001†    |
| Diabetic             | 5% (21)          | 25% (25)           | <0.001†    |
| Censored age, years  | 61.9±9.1         | 70.7±9.7           | <0.001*    |

Mean±1 SD. Numbers after percents are frequencies. apoA1 indicates apolipoprotein A1; AREase, PON1 arylester hydrolysis rate; CAAD, carotid artery disease; HDL-C, high-density lipoprotein cholesterol. Tests used: *Wilcoxon rank sum test; †Pearson chi-square test. ‡Censored age defined as the age at CAAD diagnosis (for CAAD cases) or the age at enrollment of controls.
negatively associated with CAAD (OR=0.97 [95% CI: 0.95 to 0.98], P<0.00011; Table 5). In addition, PON1 AREase activity was negatively associated with and improved model prediction of CAAD (0.7% of CAAD variation; OR=0.99 [95% CI: 0.98 to 0.99], P<0.001) in men. A 10-mg/dL increase in HDL-3 was calculated to decrease the odds of CAAD by ≈26% (OR=0.74 [95% CI: 0.63 to 0.86]), whereas a 10-IU increase in PON1 AREase activity was estimated to independently decrease the odds of CAAD by ≈7% (OR=0.93 [95% CI: 0.89 to 0.96]). In the smaller female group, HDL-3 was the only HDL phenotype included in the final regression model (0.7% of CAAD variation; OR=0.97 [95% CI: 0.95 to 0.99], P=0.042; Table 6). In women, a 10-mg/dL increase in HDL-3 was calculated to decrease the odds of CAAD by ≈24% (OR=0.76 [95% CI: 0.58 to 0.99]). Although underpowered, post hoc analysis found no evidence of interaction (P>0.05) between either HDL-3 levels or PON1 AREase activity with any demographic covariate (censored age) or clinical covariate (smoking and diabetes status).

**Discussion**

In the current study, we have used a CAAD case-control cohort of participants with European ancestry to evaluate the effects of apoA1, HDL-C, HDL-2 HDL-3, and PON1 AREase activity on CAAD risk separately in men (n=1201) and women (n=524). Using stepwise regression to find the best predictor of CAAD from the highly correlated lipid measurements of apoA1, HDL-C, HDL-2, and HDL-3, we have identified HDL-3 as the HDL phenotype that captures the most CAAD status variance in both men and women. With HDL-3 in the regression model, none of the remaining HDL-related measurements, except PON1 AREase level, improved the model for CAAD. We noted no potential confounding of age on HDL lipoprotein levels that could negate our findings. PON1 AREase activity had a significant impact on CAAD risk that was independent of HDL-3 levels in men only. To the best of our knowledge, this represents the first CAAD case-control study with population-based controls to evaluate the effects of HDL subspecies on CAAD risk.

Prior work on the associations of HDL-2 and HDL-3 with CVD has yielded conflicting results. In a recent literature review, it was reported that 45% of 37 total case-control studies found a statistically significant decrease in CVD cases for both HDL-2 and HDL-3 levels, 26% found a significant decrease in HDL-2 only, 11% found a significant decrease in HDL-3 only, and 17% found no statistically significant decrease in either HDL subfraction. The vast majority of these studies collected CHD cases; to the best of our knowledge, only one prior study has looked at CAAD: Atger et al examined 181 asymptomatic hypercholesterolemic men...

---

**Table 5.** Best-Fit Model From Stepwise Linear Regression Predicting CAAD Status in Men Using Lipid and Clinical Covariates (N=1201)

|                                      | Odds Ratio (95% CI) | % CAAD Variation | P Value   |
|--------------------------------------|--------------------|------------------|-----------|
| Intercept                            | 0.0055 (0.0013 to 0.022) | —                | <0.001    |
| Censored age, years*                 | 1.10 (1.09 to 1.13)  | 11.18            | <0.001    |
| Current smoker                       | 5.63 (3.74 to 8.62)  | 7.31             | <0.001    |
| Diabetic                             | 3.41 (2.38 to 4.95)  | 4.44             | <0.001    |
| HDL-3, mg/dL                         | 0.97 (0.95 to 0.98)  | 1.59             | 0.00011   |
| PON1 AREase activity, IU             | 0.99 (0.98 to 0.99)  | 0.68             | <0.001    |

Mean±1 SD. AREase indicates PON1 arylester hydrolysis rate; CAAD, carotid artery disease; HDL, high-density lipoprotein.

*Censored age defined as the age at CAAD diagnosis (for CAAD cases) or the age at enrollment of controls.
by ultrasound to determine the presence of CAAD, in addition to femoral and abdominal aorta stenosis. No significant difference in either HDL-2 and HDL-3 levels was found between 43 men with CAAD compared with the 138 other men.28 We note, however, that their case sample size was only 7% of our size (586 in our study versus 43 in their study); thus, they lacked power to detect the effects of HDL-3 that we identified.

The majority of prior work on the subject of HDL subfractions and CVD was done in studies of CHD and found a stronger association of HDL-2 with cardioprotection.27,29-32 One hypothesis for this correlation related to the much higher density of apoA1 on the larger HDL-2 molecule compared with HDL-3. We evaluated this hypothesis in the current study through inclusion of apoA1 as one of the possible HDL-related covariates in the stepwise regression model; however in our analyses, HDL-3 was the best predictor of CAAD variance, and with HDL-3 in the regression model, none of the other HDL-related covariates (HDL-C, HDL-2, or apoA1) were able to improve prediction of CAAD status. We note that HDL-3 is associated with other apolipoproteins, namely, A2, A3, A4, and pre-B1.13 Because these were not measured in the current study, we were unable to evaluate their individual effects on CAAD risk.

HDL-3 is the smaller, denser, and more lipid-poor of the 2 subfractions of HDL. HDL-3 is strongly antioxidant, and in prior work, it has been demonstrated that the antioxidant capability of HDL increases with density.33 In addition, HDL-3 is closely associated with the glycoprotein enzyme PON1.34 PON1 is itself atheroprotective14,35-37 and can prevent low-density lipoprotein oxidation38,39 and HDL oxidation40 (other functions of PON1 are summarized in a recent review article41). To address the possibility that our association of HDL-3 with CAAD was due to the effects of its association with PON1, we included PON1 AREase activity as a covariate in the stepwise regression model. Interestingly, in men, both HDL-3 and PON1 AREase activity were retained in the final model, suggesting that the atheroprotective effects of HDL-3 are independent and additive of PON1 enzyme activity. As noted previously, the molecular mechanisms for this association of HDL-3 with CAAD could be due to unmeasured apolipoproteins with which HDL-3 is correlated. It is notable that HDL-3 likely has antioxidant properties that are independent of PON1.33 The lack of detection of an additional PON1 effect in women may have been due to insufficient statistical power in that smaller group.

Our finding of HDL-3 being the best predictor of CAAD status is incongruent with many studies that have used similar multivariate regression methods and found HDL-2 to be more significantly associated; however, as noted above, the majority of past work regarding HDL-2 and HDL-3 has focused on CHD rather than CAAD. Although both disease states are driven by atherosclerosis, the underlying pathogenesis is likely different,42 as shown by the divergence of genes that are associated with myocardial infarction43,44 versus ischemic stroke45,46 or carotid intimal media thickening47 (no genomewide association study has been performed for CAAD to date). In this context, our finding of HDL-3 being most strongly associated, independent of PON1, may represent further evidence that the pathology of CAAD is distinct.

Several limitations of the current study must be considered. First, this cohort was composed only of participants of European ancestry, limiting inferences from our data to participants of other races. Second, men composed the majority of both the cohort and the CAAD cases (102 women versus 586 men), leaving our female-only analyses statistically less powered. Third, due to confounding with CAAD status, our analyses could not adjust for the effects of statin use on HDL-C, HDL-2, and HDL-3 levels. Although underpowered, there was no statistically significant evidence for an increase in HDL levels in 57 male participants in pre– and post–statin-initiation data. Similarly, data from the COMParative Effects on Lipid Levels of Niaspan and a Statin versus Other Lipid-Modifying Therapies (COMPELL) study, which studied the effects of 4 different statins on lipid profiles in 292 participants (50% female), did not show a statistically significant increase in HDL-3 levels at 8- or 12-week follow-up.48 Regardless, the excess of

| Odds Ratio (95% CI) | % CAAD Variation | P Value |
|--------------------|------------------|---------|
| Intercept           | 0.00063 (0.00005 to 0.0007) | —       | <0.001 |
| Censored age, years*| 1.11 (1.08 to 1.15) | 12.62   | <0.001 |
| Current smoker      | 3.56 (1.48 to 8.31) | 5.05    | 0.0036 |
| Diabetic            | 3.89 (1.82 to 8.35) | 1.51    | <0.001 |
| HDL-3, mg/dL        | 0.97 (0.95 to 0.99) | 0.70    | 0.042  |

Mean±1 SD. CAAD indicates carotid artery disease; CI, confidence interval; HDL, high-density lipoprotein.

*Censored age defined as the age at CAAD diagnosis (for CAAD cases) or the age at enrollment of controls; HDL, high-density lipoprotein.

Table 6. Best-Fit Model From Stepwise Linear Regression Predicting CAAD Status in Women Using Lipid and Clinical Covariates (N=524)
statin use in cases would result in more conservative testing of our hypothesis of HDL phenotype differences between CAAD cases and controls if statin use does increase HDL levels, as found elsewhere.49

In conclusion, our analysis of HDL subfraction data and CAAD has found that, of the subphenotypes apolA1, HDL-C, HDL-2, and HDL-3, only HDL-3 best predicts CAAD risk and the remaining phenotypes do not add significant predictive power. The effects of HDL-3 were independent of and additive with PON1 enzyme activity. Given the importance of CAAD as a risk factor for ischemic stroke and as a marker of CVD, further work elucidating the molecular mechanisms through which HDL-3 is cardioprotective for CAAD is warranted.

Acknowledgments
We would like to thank all participants of the Carotid Lesion Epidemiology and Risk (CLEAR) study.

Sources of Funding
This work was funded in part by National Institutes of Health R01 HL67406 and a State of Washington Life Sciences Discovery Award (265508) to the Northwest Institute of Genetic Medicine. D.S.K. was supported in part by the Benjamin and Margaret Hall Endowed Fellowship in Genome Sciences, a Markey Foundation award, and National Institutes of Health RO1 HL67406 and a State of Washington Life Sciences Collaborative Group. This work was funded in part by National Institutes of Health T31HG000035-18 and 1F31MH101905-01.

Disclosures
None.

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McBuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey NK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.

2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo SL, Bartels DH, Bell ML, Benjamin EJ, Bennett JD, Bhatta K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J,Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Couve BC, Criqui MH, Cross M, Dabbahskar KC, Dahodwala N, De Leo D, Degenhardt L, Delatouret A, Denenberg J, Jariatsis D, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FRG, Franklin R, Fransen M, Freeman MK, Gabriel A, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoerau H, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Kharkiyan G, Kassem M, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.

3. ECST. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet. 1991;337:1235–1243.

4. ECST. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet. 1996;347:1591–1593.

5. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453.

6. Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis. A population-based study. Arterioscler Thromb Vasc Biol. 1993;13:661–668.

7. Steg PG, Bhatt DL, Wilson PWF, D’Agostino R, Ohman EM, Røther J, Liu C-S, Hirsch AT, Mass J-L, Ikeda Y, Pencina MJ, Goto S. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206.

8. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106:1191–1200.

9. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Despins-Nickens P, Kowciwicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.

10. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbaric M, Jensen MK, Hindy G, Hölm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thøleff-Glønssen L, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheden D, Chen L, Stewart AF, Schillert A, Thorsteindottir U, Thorgerisson G, Anand S, Engert JC, Morgan T, Stupp J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki M-L, Penttinen PM, Haivurla A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland van der Zee A-H, Peters BM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer BM, Elbers CC, Onland-Moret NC, Holker MH, Wijmenga C, Verschuren WM, Boer J, van der Schouw YT, Schraadt A, Sordet O, Willer C, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyssehaert I, Lombachts D, Van de Werf F, Fox KA, El Molchian NE, Rubin D, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. Lancet. 2012;380:572–580.

11. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012;60:508–516.

12. Vaisar T, Pennathur S, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic K, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao X-Q, Elkon K, Marcovina S, Rider P, Oram JF, Heinicke JW. Shotgun proteomics implicates protease inhibition and complement activation in the inflammatory properties of HDL. J Clin Invest. 2011;127:746–756.

13. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol. 2011;22:176–185.

14. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441–2447.

15. Jarvik GP, Hatsukami TS, Richter RJ, Schellenberg GD. Paraoxonase 1 enzyme activity. J Lipid Res. 2012;53:2450–2458.

16. Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, Furlong CE. PARAOXONASE1 (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441–2447.

17. Kim DS, Burt AA, Crosslin DR, Robertson PD, Ranchalis JE, Boyko EJ, Nickerson DA, Furlong CE, Jarvik GP. Novel common and rare genetic determinants of paraoxonase activity: PON1 variants affect the relationship between dietary and total plasma cholesterol. J Lipid Res. 2013;54:552–560.

18. Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, Furlong CE, Jarvik GP. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J Lipid Res. 2013;54:1512–1520.

19. Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Eintracht JF, Roseenthal EA, Furlong CE, Jarvik GP. Additional common polymorphisms in the PON Gen Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids. 2012;2012:7467361.
22. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet. 2005;37:549–554.

23. Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL. Whole-genome genotyping with the single-base extension assay. Nat Methods. 2006;3:31–33.

24. Marcovina SM, Albers JH, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 1993;39:773–781.

25. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Cir Cardiovasc Genet. 2008;1:147–157.

26. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol. 2009;235:1–9.

27. Supero KB, Pendlaya L, Williams PT, Momay KM, King SB, Garrett BC. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012;6:496–523.

28. Atger V, Giral P, Simon A, Cambillau M, Levenson J, Gariepy J, Megnien JL, Candusso P, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia susceptible to organophosphate toxicity and atherosclerosis. PCVMETRA Group. Prat Travail. 1995;95:127–131.

29. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098–1105.

30. Asztalos BF, Batista M, Horvath KV, Cox DE, Dallal GE, Morse JS, Brown GB, Asztalos EF, Roberts R, Anderson D, Arteriosclerosis C, Cardiogenics, Carlquist JF, Chen L, Cichon S, Dodd V, Davies RW, Dedoussis G, D’cruz J, Demissie S, Devaneay JM, Diemert P, Do R, Doering A, Ebert S, Mokhtari NEE, Ellis SG, Elouga R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyre J, Gigante B, Girielli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jukema JW, Kaiser MA, Kaplan LM, Kastelen JJP, Khaw K-T, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Letter G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Mauoch S, Martiniell N, McKoecon PP, Meisinger C, Mettinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mosher TM, Munsell T, Musunuru K, Nahrstaedt J, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–338.

31. Taylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng Y-C, Fornage M, Ikram MA, Malik R, Bevan S. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–962.

32. Ikram MA, Seshadri S, Bis JC, Delacorte R, Albusoni E, Zijlstra F, van Duijn CM, Breteler MM, Longstreth WT, Wolf PA. Genomewide association studies of stroke. N Engl J Med. 2009;360:1718–1728.

33. Bis JC, Kavoussi M, Franceschini N, Isaacs A, Abecasis GR, Schmink U, Post WS, Avp, Cupples LA, Markus HS, Schadt R, Huffman JE, Lehtimakki T, Baumbert J, Munzel T, Beckert SR, Delacorte R, North K, Oostra B, Bevan S, Stoegerer E-M, Hayward C, Takataki O, Meisinger C, Schillert A, Sanna S, Vidal C, Cheng Y-C, Kastelein JP, Witteman JCM, van de Witte LW, Chilukoti RK, Harris TB, Wolf PA, Bevan S, €O€unzel T, Musunuru K, Nahrstaedt J, et al. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011;43:940–947.

34. McNeney JM, Jones PH, Bays HE, Kavoussi MV, Kashyap ML, Ruoff GE, McCravey ME. Comparative effects on lipid levels of combination therapy with niacin and simvastatin versus simvastatin alone. J Am Coll Cardiol. 2003;42:1881–1888.

35. Bergmeier C, Siekmire R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem. 2004;50:2309–2315.

36. Mackness MI, Harty D, Bhattachar A, Denning PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1993;106:193–199.

37. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287.

38. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–1270.

39. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–135.

40. Aviram M, Rosenblat M, Bigaier CL, Newton RS, Koh, X, Kristoffersson U, Norrving B, Melander O, Lindgren A. Are 25 SNPs from the CARDIOGRAM study associated with ischaemic stroke? Eur J Neurol. 2013;20:1284–1291.